Skip to main content
. 2016 Sep 21;8:475–484. doi: 10.2147/CEOR.S114524

Figure 2.

Figure 2

Kaplan–Meier curves for PFS and OS and predicted PFS and OS from the model.

Abbreviations: GClb, obinutuzumab + chlorambucil; OS, overall survival; PFS, progression-free survival; RClb, rituximab + chlorambucil.